The NeurologyLive® dementia and Alzheimer disease clinical focus page provides information, podcasts, videos, and news about the latest FDA actions, clinical guideline updates, study and clinical trial findings, and interviews with physicians related to the care of patients with dementia and similar diseases, including Lewy body dementia, frontotemporal dementia, Alzheimer disease, and more.
May 16th 2025
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 16, 2025.
Burst Expert Illustrations & Commentary™: Visualizing the Role of FcRN in Neurological Disorders
View More
BURST Expert Illustrations and Commentaries™: Visualizing FcRn as a Therapeutic Target in Neurological Disease
View More
BURST Expert Illustrations and Commentaries™: Visualizing the Implications of FcRN-Targeted Therapies on Generalized Myasthenia Gravis
View More
Clinical Consultations™: Navigating the Evolving Treatment Landscape in Generalized Myasthenia Gravis
View More
Burst Expert Illustrations & Commentary™: Visualizing the Role of Subcutaneous Infusion as an Alternate Administration Route for Medical Interventions
View More
SimulatED™: Diagnosing and Treating Alzheimer’s Disease in the Modern Era
View More
SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy
View More
Expert Illustrations & Commentaries™: New Targets for Treatment in Cognitive Impairment in Schizophrenia – The Role of NMDA Receptors and Co-agonists
View More
BURST CME™ Part I: Understanding the Impact of Huntington’s Disease
View More
Burst CME™ Part II: The Evolving Treatment Landscape for Huntington Disease
View More
Carolina Neuromuscular Disease Summit
September 27, 2025
Register Now!
SimulatEd™ From Discomfort to Relief: Acute Pain Management Essentials
View More
Evolving Perspectives in Alzheimer's Disease: Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
View More
Clinical ShowCase: Developing a Personalized Treatment Plan for a Patient with Huntington’s Disease Associated Chorea
View More
Medical Crossfire®: Integrating Real-World Data to Improve Outcomes for Patients With Multiple Sclerosis
View More
Medical Crossfire® - Optimizing Management for Patients With Generalized Myasthenia Gravis: Focus on Complement Inhibitors
View More
Burst CME™: Setting the Stage – Individualizing Migraine Care for Diverse Populations Across Care Settings
View More
Burst CME™: The Patient Journey – Unmet Needs From Diagnosis Through Management of Migraine
View More
Evolving Perspectives in Alzheimer Disease : Reaching an Earlier Diagnosis, Understanding Neuroinflammation, and Exploring Therapeutic Advances
View More
Burst CME™: Optimizing the Use of CGRP Targeted Agents for the Treatment of Migraine
View More
Burst CME™: Optimizing Migraine Management – Addressing Unmet Needs, Individualizing Care for Diverse Populations, and Utilizing CGRP Targeted Agents
View More
Community Practice Connections™: Optimizing the Management of Tardive Dyskinesia—Addressing the Complexity of Care With Targeted Treatment
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
Patient, Provider, and Caregiver Connection™: Pediatric Myasthenia Gravis—Current Treatment and Emerging Concepts
View More
Mind Moments™: Optimizing Management for Patients with Generalized Myasthenia Gravis
View More
Cases and Conversations™: Navigating the Complexities of Managing Myasthenia Gravis in Pediatric and Pregnant Patient Populations
View More
Cases and Conversations™: Little Voices, Big Challenges – Comprehensive Care for Pediatric Spinal Muscular Atrophy
View More
Identifying and Treating CIDP in the Modern Era
View More
A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One
View More
Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients
View More
Hormonal and Neurological Complexity in Traumatic Brain Injury Recovery for Women
May 4th 2025Christine Greiss, DO, medical director for the Center for Brain injuries at Hackensack Meridian Health, discussed the nuanced impact of hormonal fluctuations, psychological factors, and postmenopausal status on TBI recovery in women.
Honoring 2025 SEQUINS Hall of Famers: Perspectives From Cheryl Bushnell, MD, MHS
May 1st 2025Cheryl Bushnell, MD, MHS, a professor of neurology at Wake Forest University, discussed her SEQUINS Hall of Fame recognition, her work on sex differences in stroke risk, and her ongoing efforts to improve stroke care equity.
How Personalized Repetitive Transcranial Magnetic Stimulation May Transform Alzheimer Treatment
April 20th 2025Ken Mariash, chief executive officer at Sinaptica, provided commentary on new data from the company’s SinaptiStim neuromodulation system, highlighting its clinical promise in slowing Alzheimer disease progression through targeted, non-drug brain network stimulation.
A New Era in Research: Exploring Cognitive Health and Alzheimer Disease in Down Syndrome
April 14th 2025Elizabeth Head, PhD, a professor in the Department of Pathology and Laboratory Medicine at the University of California, Irvine, shed light on the emerging research and trials surrounding the interplay between Alzheimer disease and Down syndrome.
Revolutionizing Neurology Care: Previewing Cleveland Clinic’s New Neurological Institute
April 11th 2025Cleveland Clinic’s $1.1 billion Neurological Institute, opening in 2027, will revolutionize neurological care with a state-of-the-art, patient-centered design integrating advanced technology and innovative care solutions.
Challenges in Treating Genetically Predisposed Alzheimer Disease: Insights from APOLLOE4
April 11th 2025Emer MacSweeney, MD, a consultant neuroradiologist and trial investigator of the phase 3 APOLLOE4 study, provided a clinical view of the latest study findings, and the difficulties with finding treatments for APOEε4/4 carriers of Alzheimer disease.
Educating the Clinical Community on Differences in Alzheimer Diagnostic Criteria: Clifford Jack, MD
April 10th 2025The neuroradiologist at Mayo Clinic provided clinical insights on the controversy with two recently published Alzheimer criteria, with one diagnosing the disease based on biomarkers alone vs clinical symptoms. [WATCH TIME: 4 minutes]
Phase 3 INFRONT-3 Study Details Baseline Characteristics of Participants With FTD-GRN
April 8th 2025A phase 3 trial investigating latozinemab, a monoclonal antibody therapy for frontotemporal dementia because of GRN mutations, reported baseline participant characteristics to better characterize this patient population.
The Evolving and Emerging Role of Plasma Biomarkers in Diagnosing and Monitoring Alzheimer Disease
April 5th 2025Inge Verberk, PhD, a research associate at the Amsterdam University Medical Center, sat down at AD/PD 2025 to discuss changes in Alzheimer trials, the emergence of plasma biomarkers, and deciphering which biomarkers are of utmost importance.
Novel IVD Tool for Rapid APOE Genotyping May Aid in Alzheimer Disease Risk Stratification
April 4th 2025A recent poster presentation at the 2025 AD/PD conference revealed that a novel assay could provide absolute allelic discrimination for APOE genotyping, supporting precision medicine in AD treatment.
Sweden Analysis Reveals Key Lifestyle and Socioeconomic Factors Driving Cognitive Decline
April 4th 2025An analysis of the Gothenburg Mild Cognitive Impairment Study presented at the 2025 AD/PD Conference reported that lifestyle and socioeconomic factors could significantly influence the risk of developing cognitive diseases.